Applied Clinical Trials
Medidata Solutions
Site performance is a critical factor in the success of any clinical trial. Sponsors are continually looking for ways to better track site performance and minimize the number of sites that fail to enroll a patient. To that end, Medidata has tracked two metrics related to the performance of investigative sites, the percentages of both non-enrolling and high-enrolling sites. A non-enrolling site is a site that actively participated in a clinical trial but failed to recruit any patients.
Nearly one-third of sites performing clinical trials never enroll a single patient.
Non-enrolling sites contribute significantly to both study delays and unnecessary costs. Drawn from the more than 2,000 studies in the Medidata InsightsTM metric warehouse, the non-enrolling site performance metric shown in the graph illustrates that nearly one-third of sites performing clinical trials never enroll a single patient. While Asia Pacific is clearly the best performing geographic region at just more than 17%, in certain geographies the percentage is over 40%.
At tens of thousands of dollars in site initiation and maintenance costs per site, wouldn't it be nice to be able to eliminate or at least reduce the number of non-productive sites? What can be done to drive better site selection and performance? We'd love to hear your take on these results.
Please continue to stay tuned as we look further into Insights data throughout 2012.
—Medidata Solutions, www.mdsol.com
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Twice-Yearly Lenacapavir Injections Significantly Reduce HIV Risk, PURPOSE 2 Trial Shows
November 13th 2024Full Phase III PURPOSE 2 trial results suggest that twice-yearly lenacapavir could revolutionize HIV prevention by offering a convenient and effective long-acting option for individuals at risk of infection.